Abnormal white matter microstructure in drug-naive first episode schizophrenia patients before and after eight weeks of antipsychotic treatment

Schizophrenia Research

Volumn 172, Issue 1-3, 2016, Pages 1-8

  Zeng, Botao ^a,b   Ardekani, Babak A ^c,d   Tang, Yingying ^a   Zhang, Tianhong ^a   Zhao, Shanshan ^a   Cui, Huiru ^a   Fan, Xiaoduo ^e   Zhuo, Kaiming ^a   Li, Chunbo ^a,f   Xu, Yifeng ^a,f   Goff, Donald C ^c,d   Wang, Jijun ^a,f  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG MENTAL HEALTH CENTER   (China)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^e UMASS MEMORIAL MEDICAL CENTER   (United States)

^f SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cognition; Diffusion tensor imaging; Longitudinal observation; Medication na ve; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; AXIAL DIFFUSIVITY; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIFFUSION TENSOR IMAGING; FEMALE; FOLLOW UP; FRACTIONAL ANISOTROPY; HUMAN; INFERIOR LONGITUDINAL FASCICULUS; MAJOR CLINICAL STUDY; MALE; MEAN DIFFUSIVITY; NEGATIVE SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITOFRONTAL FASCICULUS; PHYSICAL PARAMETERS; POSITIVE SYNDROME; PRIORITY JOURNAL; PYRAMIDAL TRACT; RADIAL DIFFUSIVITY; SCHIZOPHRENIA; SCORING SYSTEM; SUPERIOR LONGITUDINAL FASCICULUS; THALAMUS ANTERIOR NUCLEUS; UNCINATE FASCICULUS; VISUAL MEMORY; WHITE MATTER; WHITE MATTER LESION; WORKING MEMORY; ACUTE DISEASE; ANISOTROPY; BRAIN; DIAGNOSTIC IMAGING; DRUG EFFECTS; LONGITUDINAL STUDY; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; ANISOTROPY; ANTIPSYCHOTIC AGENTS; BRAIN; CROSS-SECTIONAL STUDIES; DIFFUSION TENSOR IMAGING; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGING, THREE-DIMENSIONAL; LONGITUDINAL STUDIES; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; WHITE MATTER; YOUNG ADULT;

EID: 84956708500     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.01.051     Document Type: Article

References (66)

1. Andreasen N.C. Scale for the Assessment of Negative Symptoms 1983, University of Iowa, Iowa City.
2. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatr. 2005, 162(3):441-449.
3. Asami T., Hyuk Lee S., Bouix S., Rathi Y., Whitford T.J., Niznikiewicz M., Nestor P., McCarley R.W., Shenton M.E., Kubicki M. Cerebral white matter abnormalities and their associations with negative but not positive symptoms of schizophrenia. Psychiatry Res. 2014, 222(1-2):52-59.
4. Bernal B., Altman N. The connectivity of the superior longitudinal fasciculus: a tractography DTI study. Magn. Reson. Imaging 2010, 28(2):217-225.
5. Bijanki K.R., Hodis B., Magnotta V.A., Zeien E., Andreasen N.C. Effects of age on white matter integrity and negative symptoms in schizophrenia. Schizophr. Res. 2015, 161(1):29-35.
6. Cheung V., Cheung C., McAlonan G., Deng Y., Wong J., Yip L., Tai K., Khong P., Sham P., Chua S. A diffusion tensor imaging study of structural dysconnectivity in never-medicated, first-episode schizophrenia. Psychol. Med. 2008, 38(06):877-885.
7. Cheung V., Cheung C., McAlonan G.M., Deng Y., Wong J.G., Yip L., Tai K.S., Khong P.L., Sham P., Chua S.E. A diffusion tensor imaging study of structural dysconnectivity in never-medicated, first-episode schizophrenia. Psychol. Med. 2008, 38(6):877-885.
8. Cheung V., Chiu C.P., Law C.W., Cheung C., Hui C.L., Chan K.K., Sham P.C., Deng M.Y., Tai K.S., Khong P.L., McAlonan G.M., Chua S.E., Chen E. Positive symptoms and white matter microstructure in never-medicated first episode schizophrenia. Psychol. Med. 2011, 41(8):1709-1719.
9. Epstein K.A., Cullen K.R., Mueller B.A., Robinson P., Lee S., Kumra S. White matter abnormalities and cognitive impairment in early-onset schizophrenia-spectrum disorders. J. Am. Acad. Child Adolesc. Psychiatry 2014, 53(3):362-372. (e362).
10. Federspiel A., Begré S., Kiefer C., Schroth G., Strik W.K., Dierks T. Alterations of white matter connectivity in first episode schizophrenia. Neurobiol. Dis. 2006, 22(3):702-709.
11. Filippi M., Canu E., Gasparotti R., Agosta F., Valsecchi P., Lodoli G., Galluzzo A., Comi G., Sacchetti E. Patterns of brain structural changes in first-contact, antipsychotic drug-naive patients with schizophrenia. AJNR Am. J. Neuroradiol. 2014, 35(1):30-37.
12. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-I/P Version 2.0), January 1995 Final. New York, NY: Biometrics Research Department, New York State Psychiatric Institute 1995.
13. Gasparotti R., Valsecchi P., Carletti F., Galluzzo A., Liserre R., Cesana B., Sacchetti E. Reduced fractional anisotropy of corpus callosum in first-contact, antipsychotic drug-naive patients with schizophrenia. Schizophr. Res. 2009, 108(1):41-48.
14. George B., Lu P.H., Amar C.P., Raven E.P., Detore N.R., Altshuler L.L., Jim M., Joseph V., Casaus L.R., Luo J.S. Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr. Res. 2011, 132(1):35-41.
15. Guo W., Liu F., Liu Z., Gao K., Xiao C., Chen H., Zhao J. Right lateralized white matter abnormalities in first-episode, drug-naive paranoid schizophrenia. Neurosci. Lett. 2012, 531(1):5-9.
16. Hao Y., Liu Z., Jiang T., Gong G., Liu H., Tan L., Kuang F., Xu L., Yi Y., Zhang Z. White matter integrity of the whole brain is disrupted in first-episode schizophrenia. Neuroreport 2006, 17(1):23-26.
17. Hatton S.N., Lagopoulos J., Hermens D.F., Hickie I.B., Scott E., Bennett M.R. White matter tractography in early psychosis: clinical and neurocognitive associations. Journal of Psychiatry & Neuroscience: JPN 2014, 39(6):417-427.
18. Hubl D., Koenig T., Strik W., Federspiel A., Kreis R., Boesch C., Maier S.E., Schroth G., Lovblad K., Dierks T. Pathways that make voices: white matter changes in auditory hallucinations. Arch. Gen. Psychiatry 2004, 61(7):658-668.
19. Jenkinson M., Smith S. A global optimisation method for robust affine registration of brain images. Med. Image Anal. 2001, 5(2):143-156.
20. Kahn R.S., Sommer I.E. The neurobiology and treatment of first-episode schizophrenia. Mol. Psychiatry 2015, 20(1):84-97.
21. Koch K., Wagner G., Dahnke R., Schachtzabel C., Schultz C., Roebel M., Gullmar D., Reichenbach J.R., Sauer H., Schlosser R.G. Disrupted white matter integrity of corticopontine-cerebellar circuitry in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2010, 260(5):419-426.
22. Konrad A., Winterer G. Disturbed structural connectivity in schizophrenia - primary factor in pathology or epiphenomenon?. Schizophr. Bull. 2008, 34(1):72-92.
23. Kubicki M., Westin C.-F., Nestor P.G., Wible C.G., Frumin M., Maier S.E., Kikinis R., Jolesz F.A., McCarley R.W., Shenton M.E. Cingulate fasciculus integrity disruption in schizophrenia: a magnetic resonance diffusion tensor imaging study. Biol. Psychiatry 2003, 54(11):1171-1180.
24. Kubicki M., Park H., Westin C.F., Nestor P.G., Mulkern R.V., Maier S.E., Niznikiewicz M., Connor E.E., Levitt J.J., Frumin M., Kikinis R., Jolesz F.A., McCarley R.W., Shenton M.E. DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. NeuroImage 2005, 26(4):1109-1118.
25. Kubicki M., McCarley R., Westin C.-F., Park H.-J., Maier S., Kikinis R., Jolesz F.A., Shenton M.E. A review of diffusion tensor imaging studies in schizophrenia. J. Psychiatr. Res. 2007, 41(1-2):15-30.
26. Kubicki M., McCarley R., Westin C.-F., Park H.-J., Maier S., Kikinis R., Jolesz F.A., Shenton M.E. A review of diffusion tensor imaging studies in schizophrenia. J. Psychiatr. Res. 2007, 41(1):15-30.
27. Kyriakopoulos M., Samartzis L., Dima D., Hayes D., Corrigall R., Barker G., Correll C., Frangou S. P03-111-does antipsychotic medication affect white matter in schizophrenia and bipolar disorder? A review of diffusion tensor imaging literature. Eur. Psychiat. 2011, 26:1280.
28. Lee D.Y., Smith G.N., Su W., Honer W.G., Macewan G.W., Lapointe J.S., Vertinsky A.T., Vila-Rodriguez F., Kopala L.C., Lang D.J. White matter tract abnormalities in first-episode psychosis. Schizophr. Res. 2012, 141(1):29-34.
29. Lee S.H., Kubicki M., Asami T., Seidman L.J., Goldstein J.M., Mesholam-Gately R.I., McCarley R.W., Shenton M.E. Extensive white matter abnormalities in patients with first-episode schizophrenia: a Diffusion Tensor Iimaging (DTI) study. Schizophr. Res. 2013, 143(2-3):231-238.
30. Li Q., Cheung C., Wei R., Cheung V., Hui E.S., You Y., Wong P., Chua S.E., McAlonan G.M., Wu E.X. Voxel-based analysis of postnatal white matter microstructure in mice exposed to immune challenge in early or late pregnancy. NeuroImage 2010, 52(1):1-8.
31. Liu X., Lai Y., Wang X., Hao C., Chen L., Zhou Z., Yu X., Hong N. Reduced white matter integrity and cognitive deficit in never-medicated chronic schizophrenia: a diffusion tensor study using TBSS. Behav. Brain Res. 2013, 252:157-163.
32. Lukoff D., Nuechterlein K., Ventura J. Manual for the expanded brief psychiatric rating scale. Schizophr. Bull. 1986, 12:594-602.
33. Mandl R.C., Rais M., Baal G.C.M., Haren N.E., Cahn W., Kahn R.S., Pol H.E.H. Altered white matter connectivity in never-medicated patients with schizophrenia. Hum. Brain Mapp. 2013, 34(9):2353-2365.
34. Nakamura K., Kawasaki Y., Takahashi T., Furuichi A., Noguchi K., Seto H., Suzuki M. Reduced white matter fractional anisotropy and clinical symptoms in schizophrenia: a voxel-based diffusion tensor imaging study. Psychiatry Res. 2012, 202(3):233-238.
35. Nestor P.G., Kubicki M., Spencer K.M., Niznikiewicz M., McCarley R.W., Shenton M.E. Attentional networks and cingulum bundle in chronic schizophrenia. Schizophr. Res. 2007, 90(1):308-315.
36. Nuechterlein K., Green M., Kern R., Baade L., Barch D., Cohen J., Essock S., Fenton W., Frese F., Gold J. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am. J. Psychiatr. 2008, 165(2):203-213.
37. Panos Roussos V.H. Schizophrenia: susceptibility genes and oligodendroglial and myelin related abnormalities. Front. Cell. Neurosci. 2014, 8(2):5.
38. Park J.Y., Park H.J., Kim D.J., Kim J.J. Positive symptoms and water diffusivity of the prefrontal and temporal cortices in schizophrenia patients: a pilot study. Psychiatry Res. 2014, 224(1):49-57.
39. Pérez-Iglesias R., Tordesillas-Gutiérrez D., McGuire P.K., Barker G.J., Roiz-Santiañez R., Mata I., de Lucas E.M., Rodríguez-Sánchez J.M., Ayesa-Arriola R., Vazquez-Barquero J.L. White matter integrity and cognitive impairment in first-episode psychosis. Am. J. Psychiatry 2010, 167(4):451-458.
40. Prasad K.M., Upton C.H., Nimgaonkar V.L., Keshavan M.S. Differential susceptibility of white matter tracts to inflammatory mediators in schizophrenia: an integrated DTI study. Schizophr. Res. 2015, 161(1):119-125.
41. Reis Marques T., Taylor H., Chaddock C., Dell'acqua F., Handley R., Reinders A.A., Mondelli V., Bonaccorso S., Diforti M., Simmons A., David A.S., Murray R.M., Pariante C.M., Kapur S., Dazzan P. White matter integrity as a predictor of response to treatment in first episode psychosis. Brain J. Neurol. 2014, 137(Pt 1):172-182.
42. Roalf D.R., Gur R.E., Verma R., Parker W.A., Quarmley M., Ruparel K., Gur R.C. White matter microstructure in schizophrenia: associations to neurocognition and clinical symptomatology. Schizophr. Res. 2015, 161(1):42-49.
43. Rosin C., Bates T.E., Skaper S.D. Excitatory amino acid induced oligodendrocyte cell death in vitro: receptor-dependent and-independent mechanisms. J. Neurochem. 2004, 90(5):1173-1185.
44. Rosin C., Colombo S., Calver A.A., Bates T.E., Skaper S.D. Dopamine D2 and D3 receptor agonists limit oligodendrocyte injury caused by glutamate oxidative stress and oxygen/glucose deprivation. Glia 2005, 52(4):336-343.
45. Seal M.L., Yücel M., Fornito A., Wood S.J., Harrison B.J., Walterfang M., Pell G.S., Pantelis C. Abnormal white matter microstructure in schizophrenia: a voxelwise analysis of axial and radial diffusivity. Schizophr. Res. 2008, 101(1):106-110.
46. Seki Y., Kato T.A., Monji A., Mizoguchi Y., Horikawa H., Sato-Kasai M., Yoshiga D., Kanba S. Pretreatment of aripiprazole and minocycline, but not haloperidol, suppresses oligodendrocyte damage from interferon-γ-stimulated microglia in co-culture model. Schizophr. Res. 2013, 151(1):20-28.
47. Shamy J., Carpenter D., Fong S., Murray E., Tang C., Hof P., Rapp P. Alterations of white matter tracts following neurotoxic hippocampal lesions in macaque monkeys: a diffusion tensor imaging study. Hippocampus 2010, 20(8):906-910.
48. Shi C., Kang L., Yao S., Ma Y., Li T., Liang Y., Cheng Z., Xu Y., Shi J., Xu X. The MATRICS Consensus Cognitive Battery (MCCB): co-norming and standardization in China. Schizophr. Res. 2015, 169(1-3):109-115.
49. Skelly L.R., Calhoun V., Meda S.A., Kim J., Mathalon D.H., Pearlson G.D. Diffusion tensor imaging in schizophrenia: relationship to symptoms. Schizophr. Res. 2008, 98(1):157-162.
50. Smith S.M., Jenkinson M., Woolrich M.W., Beckmann C.F., Behrens T.E., Johansen-Berg H., Bannister P.R., De Luca M., Drobnjak I., Flitney D.E. Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage 2004, 23:S208-S219.
51. Smith S.M., Jenkinson M., Johansen-Berg H., Rueckert D., Nichols T.E., Mackay C.E., Watkins K.E., Ciccarelli O., Cader M.Z., Matthews P.M. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. NeuroImage 2006, 31(4):1487-1505.
52. Spitzer R.L., Williams J.B., Gibbon M., First M. Structured Clinical Interview for DSM-III-R - Non-Patient Edition (SCID-NP, Version 1.0) 1990, American Psychiatric Press, Washington, DC.
53. Sugranyes G., Kyriakopoulos M., Dima D., O'Muircheartaigh J., Corrigall R., Pendelbury G., Hayes D., Calhoun V.D., Frangou S. Multimodal analyses identify linked functional and white matter abnormalities within the working memory network in schizophrenia. Schizophr. Res. 2012, 138(2):136-142.
54. Sun H., Lui S., Yao L., et al. Two patterns of white matter abnormalities in medication-naive patients with first-episode schizophrenia revealed by diffusion tensor imaging and cluster analysis. JAMA Psychiatry 2015, 72(7):678-686.
55. Szeszko P.R., Robinson D.G., Ashtari M., Vogel J., Betensky J., Sevy S., Ardekani B.A., Lencz T., Malhotra A.K., McCormack J., Miller R., Lim K.O., Gunduz-Bruce H., Kane J.M., Bilder R.M. Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology 2007, 33(5):976-984.
56. Szeszko P.R., Robinson D.G., Ashtari M., Vogel J., Betensky J., Sevy S., Ardekani B.A., Lencz T., Malhotra A.K., McCormack J. Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology 2008, 33(5):976-984.
57. Szeszko P.R., Robinson D.G., Ikuta T., Peters B.D., Gallego J.A., Kane J., Malhotra A.K. White matter changes associated with antipsychotic treatment in first-episode psychosis. Neuropsychopharmacology 2014, 39(6):1324-1331.
58. Tourjman V., Kouassi É., Koué M.-È., Rocchetti M., Fortin-Fournier S., Fusar-Poli P., Potvin S. Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr. Res. 2013, 151(1):43-47.
59. Turken U., Whitfield-Gabrieli S., Bammer R., Baldo J.V., Dronkers N.F., Gabrieli J.D. Cognitive processing speed and the structure of white matter pathways: convergent evidence from normal variation and lesion studies. NeuroImage 2008, 42(2):1032-1044.
60. Ventura J., Lukoff D., Nuechterlein K., Liberman R., Green M., Shaner A. Manual for the expanded brief psychiatric rating scale. Int. J. Methods Psychiatr. Res. 1993, 3:221-224.
61. Wang Q., Cheung C., Deng W., Li M., Huang C., Ma X., Wang Y., Jiang L., Sham P.C., Collier D.A., Gong Q., Chua S.E., McAlonan G.M., Li T. White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment. Psychol. Med. 2013, 43(11):2301-2309.
62. Wheeler A.L., Voineskos A.N. A review of structural neuroimaging in schizophrenia: from connectivity to connectomics. Front. Hum. Neurosci. 2014, 8:653.
63. White T., Magnotta V.A., Bockholt H.J., Williams S., Wallace S., Ehrlich S., Mueller B.A., Ho B.C., Jung R.E., Clark V.P., Lauriello J., Bustillo J.R., Schulz S.C., Gollub R.L., Andreasen N.C., Calhoun V.D., Lim K.O. Global white matter abnormalities in schizophrenia: a multisite diffusion tensor imaging study. Schizophr. Bull. 2011, 37(1):222-232.
64. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003.
65. Zahr N.M., Rohlfing T., Pfefferbaum A., Sullivan E.V. Problem solving, working memory, and motor correlates of association and commissural fiber bundles in normal aging: a quantitative fiber tracking study. NeuroImage 2009, 44(3):1050-1062.
66. Zhang Y., Zhang H., Wang L., Jiang W., Xu H., Xiao L., Bi X., Wang J., Zhu S., Zhang R., He J., Tan Q., Zhang D., Kong J., Li X.M. Quetiapine enhances oligodendrocyte regeneration and myelin repair after cuprizone-induced demyelination. Schizophr. Res. 2012, 138(1):8-17.